Compare NGNE & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | IBEX |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.8M | 386.9M |
| IPO Year | N/A | 2020 |
| Metric | NGNE | IBEX |
|---|---|---|
| Price | $20.61 | $37.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $38.50 | $31.33 |
| AVG Volume (30 Days) | ★ 188.3K | 88.1K |
| Earning Date | 11-13-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.76 |
| EPS | N/A | ★ 2.77 |
| Revenue | N/A | ★ $579,735,000.00 |
| Revenue This Year | N/A | $12.15 |
| Revenue Next Year | N/A | $5.68 |
| P/E Ratio | ★ N/A | $13.80 |
| Revenue Growth | N/A | ★ 12.86 |
| 52 Week Low | $6.88 | $20.18 |
| 52 Week High | $37.27 | $42.99 |
| Indicator | NGNE | IBEX |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 47.09 |
| Support Level | $19.28 | $38.20 |
| Resistance Level | $22.99 | $39.49 |
| Average True Range (ATR) | 1.44 | 1.00 |
| MACD | 0.32 | -0.06 |
| Stochastic Oscillator | 40.15 | 2.03 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.